Payment overview · 2025
General Payments
$2,344.27
70 reported records · 34 companies
Healthcare provider profile · identity verified
Kai Zu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · LA MESA, CA · NPI 1164583639
Verified facts
What the public records show
CMS Open Payments records show Kai Zu, M.D. received $2,344.27 in general payments during 2025 across 70 reported records.
Daiichi Sankyo Inc. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Ibrance, Imbruvica, Reblozyl.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Imbruvica by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ibrance by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xtandi by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Brukinsa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Pomalyst by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 17361 records involving 5696 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Reblozyl by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1732 records involving 943 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Reblozyl by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1175 records involving 979 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Reblozyl by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kisqali by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $650.00 | 27.7% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $220.65 | 9.4% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $150.27 | 6.4% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $101.61 | 4.3% | 4 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $99.52 | 4.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $86.72 | 3.7% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $80.91 | 3.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.24 | 3.2% | 3 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $69.56 | 3.0% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $69.17 | 3.0% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $68.14 | 2.9% | 3 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $55.54 | 2.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.09 | 2.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.30 | 2.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $44.25 | 1.9% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $42.15 | 1.8% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $36.91 | 1.6% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $30.80 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.53 | 1.3% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.32 | 1.2% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.90 | 1.2% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $25.86 | 1.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.44 | 1.0% | 1 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $23.85 | 1.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $23.55 | 1.0% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $23.40 | 1.0% | 1 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $22.38 | 0.9% | 1 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $22.34 | 0.9% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $21.06 | 0.9% | 1 | 2025 |
| Fennec Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.71 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.25 | 0.7% | 1 | 2025 |
| Acrotech Biopharma Inc. | Unresolved — no canonical attribution shown | $16.26 | 0.7% | 1 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $15.99 | 0.7% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.60 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,678.28 | 68 |
| Consulting Fee | $650.00 | 1 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $650.00 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $142.58 | 5 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $94.50 | 5 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $86.72 | 3 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $76.08 | 3 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $69.56 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $69.17 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $68.14 | 3 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $68.14 | 3 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $66.53 | 4 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $66.01 | 2 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | Celgene Corporation | $62.96 | 4 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $56.54 | 2 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $55.96 | 3 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $55.54 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $52.71 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $49.04 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $48.90 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $42.15 | 2 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| XALKORI Normalized: xalkori |
Drug | ARRAY BIOPHARMA INC | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $36.91 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $33.89 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $33.89 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $33.72 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $28.62 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| ZIIHERA Normalized: ziihera |
Drug | JAZZ PHARMACEUTICALS INC. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| SYLVANT Normalized: sylvant |
Drug | RECORDATI_RARE_DISEASES_INC. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| Fyarro Normalized: fyarro |
Drug | Fennec Pharmaceuticals, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| RYZNEUTA Normalized: ryzneuta |
Drug | Acrotech Biopharma Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ABECMA Normalized: abecma |
Biological | Celgene Corporation | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REBLOZYL reblozyl |
2025 | Reblozyl | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 17361 supporting records · 5696 recipient NPIs · example record 1184377709 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1732 supporting records · 943 recipient NPIs · example record 1184377805 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1175 supporting records · 979 recipient NPIs · example record 1237992280 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 125 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 90 | 47 |
| Omeprazole | Omeprazole | 69 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 60 | suppressed |
| Brukinsa | Zanubrutinib | 49 | suppressed |
| Prednisone | Prednisone | 48 | 16 |
| Potassium Chloride | Potassium Chloride | 47 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 38 | suppressed |
| Lenalidomide | Lenalidomide | 37 | suppressed |
| Dexamethasone | Dexamethasone | 34 | 14 |
| Reblozyl | Luspatercept-Aamt | 34 | suppressed |
| Hydroxyurea | Hydroxyurea | 31 | suppressed |
| Calquence | Acalabrutinib Maleate | 29 | suppressed |
| Ibrance | Palbociclib | 27 | suppressed |
| Kisqali | Ribociclib Succinate | 26 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Tagrisso | Osimertinib Mesylate | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | 11 |
| Letrozole | Letrozole | 22 | suppressed |
| Pomalyst | Pomalidomide | 22 | suppressed |
| Xtandi | Enzalutamide | 22 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 21 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | 13 |
| Acyclovir | Acyclovir | 19 | suppressed |
| Revlimid | Lenalidomide | 19 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Tasigna | Nilotinib Hcl | 15 | suppressed |
| Nubeqa | Darolutamide | 14 | suppressed |
| Imbruvica | Ibrutinib | 13 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 13 | suppressed |
| Retevmo | Selpercatinib | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Alunbrig | Brigatinib | 12 | suppressed |
| Danazol | Danazol | 12 | suppressed |
| Erleada | Apalutamide | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Verzenio | Abemaciclib | 12 | suppressed |
| Tavalisse | Fostamatinib Disodium | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,344.27 · 70 records | Daiichi Sankyo Inc. | ABECMA, ADCETRIS, AYVAKIT, Amtagvi, BESREMI, BEYFORTUS, BOSULIF, BRAFTOVI, BREYANZI, BRUKINSA, CARVYKTI, ELAHERE, ELREXFIO, EPKINLY, FOTIVDA, Fabhalta, Fyarro, GIVLAARI, IBRANCE, IMBRUVICA, INQOVI, JEMPERLI, KEYTRUDA, LIBTAYO, LONSURF, LORBRENA, Lenvima, MEKTOVI, OGSIVEO, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Orserdu, PADCEV, QINLOCK, REBLOZYL, ROMVIMZA, RYZNEUTA, SCEMBLIX, SYLVANT, TEVIMBRA, TUKYSA, Tibsovo, Vanflyta, WAYRILZ, WELIREG, XALKORI, XPOVIO, Yescarta, ZEJULA, ZIIHERA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error